Investor Presentaiton
LOVVOLUS
JEUVEAUⓇ
DESIGNED WITH PRECISION
900 KDA
PRABOTULINUMTOXINA
+
+
0.5 MG
0.9 MG
HUMAN SERUM ALBUMIN
SALT
De
PURIFICATION METHOD: Crystallization and
HiPure™ technology
FINISHING METHOD: Vacuum dried
A precise product with a tight field of effect¹
Puts control in the hands of the injector
Helps provide predictable, consistent and
safe outcomes
•
LOW RATES OF EYELID PTOSIS WITH JEUVEAUⓇ2
DRUG-RELATED EYELID
PTOSIS (EV-001)³
JEUVEAUⓇ
1% (2/246)
0% (0/84
DRUG-RELATED EYELID
PTOSIS (EV-002)4
Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo M, Shamban A. Re-examining the optimal use of neuromodulators
and the changing landscape: A consensus panel update. J Drugs Dermatol. 2020;19(4 suppl 1):s5-15.
Adverse Events Observed in EV-001 and EV-0027,6. Phase 3 randomized, multicenter, double-blind, placebo-
controlled US trials
1.
2.
3.
Data on file; CSR EV-001, BLA761085. Evolus, Inc., Newport Beach, CA
4.
Data on file; CSR EV-002, BLA761085. Evolus, Inc., Newport Beach, CA
PLACEBO
1% (3/246)
0% (0/78)
BOTOX AND JEUVEAU ARE THE ONLY FDA-APPROVED 900 KDA NEUROTOXINS
4View entire presentation